Processing

Please wait...

Settings

Settings

Goto Application

Offices all Languages Stemming false Single Family Member true Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

IC:C07K

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1.WO/2022/129622ROR1-SPECIFIC VARIANT ANTIGEN BINDING MOLECULES
WO 23.06.2022
Int.Class A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
Appl.No PCT/EP2021/086667 Applicant ALMAC DISCOVERY LIMITED Inventor TRUMPER, Paul Richard
The present invention relates to receptor tyrosine kinase-like orphan receptor 1 (ROR1) specific variant antigen binding molecules and associated fusion proteins, chimeric antigen receptors, nucleic acid sequences, vectors, host cells, pharmaceutical compositions, medical uses and conjugates, and methods of preparing and using the same.
2.WO/2022/129637T CELL RECRUITING POLYPEPTIDES BASED ON TCR ALPHA/BETA REACTIVITY
WO 23.06.2022
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
Appl.No PCT/EP2021/086843 Applicant ABLYNX NV Inventor NEYT, Katrijn
The present technology provides T cell recruiting polypeptides that specifically bind to the constant domain of a human and of a non-human primate TCR. The present technology also provides nucleic acids, vectors, and compositions. The polypeptides can be used in methods for treatment of cancer.
3.WO/2022/130342TETRAVALENT FZD AND WNT CO-RECEPTOR BINDING ANTIBODY MOLECULES AND USES THEREOF
WO 23.06.2022
Int.Class C07K 16/46
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
46Hybrid immunoglobulins
Appl.No PCT/IB2021/061972 Applicant ANTLERA THERAPEUTICS INC. Inventor ANGERS, Stephane
Described herein are tetravalent binding antibody molecules comprising a FZD receptor binding domain and an LRP5/6 co-receptor binding domain on opposite termini of an Fc domain that activate a Wnt beta-catenin signaling pathway and methods for their use.
4.WO/2022/132202COMBINATION THERAPY FOR THE TREATMENT OF CANCER
WO 23.06.2022
Int.Class C07K 14/495
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
475Growth factors; Growth regulators
495Transforming growth factor (TGF)
Appl.No PCT/US2021/010067 Applicant BICARA THERAPEUTICS INC. Inventor MARIGOWDA, Shivakumar, Bhadravathi
Provided herein are methods of treating cancer by administering to a subject having cancer an antibody, or functional fragment or functional variant thereof, that specifically binds programmed cell death protein 1 (PD1); and a fusion protein that comprises a targeting moiety and an immunomodulatory moiety, wherein: i) said targeting moiety specifically binds epidermal growth factor receptor (EGFR); and (ii) said immunomodulatory moiety comprises an amino acid sequence of the extracellular domain of transforming growth factor-beta receptor Il (TGFβRII).
5.WO/2022/127372CAR-INKT WITH HIGH AMPLIFICATION, SURVIVAL CAPACITY AND TUMOR KILLING EFFECT AND USE THEREOF
WO 23.06.2022
Int.Class C07K 19/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
19Hybrid peptides
Appl.No PCT/CN2021/125615 Applicant BEIJING GENE KEY LIFE TECHNOLOGY CO., LTD. Inventor LYU, Jun
Provided in the present application is a chimeric antigen receptor, including a GPC3 antigen binding domain, an ICD1, ICD2 or ICD3 intracellular signal stimulation domain with amino acid sequences of SEQ ID NOs: 29, 31 and 33, respectively, and an IL-15-IL-15α fusion protein with an amino acid sequence of SEQ ID NO:7. After the chimeric antigen receptor is transferred into immune cells, especially iNKT cells, the cell proliferation rate, survival time and tumor killing effect can be effectively improved. Further provided in the present application are a corresponding expression vector, a transduction system, a pharmaceutical use, independent ICD1, ICD2 and ICD3 intracellular signal stimulation domains, and an IL-15-IL-15α fusion protein.
6.WO/2022/133042CEA5 BINDING MOLECULES AND USES THEREOF
WO 23.06.2022
Int.Class A61K 39/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
Appl.No PCT/US2021/063727 Applicant BIOARDIS, LLC Inventor HAERIZADEH, Farzad
Disclosed herein are carcinoembryonic antigen 5 (CEA5)-specific binding polypeptides. These binding polypeptides may be incorporated into chimeric antigen receptors (CARs). Also disclosed herein are methods of using these binding polypeptides and/or CARs for the treatment of, for example, a cancer.
7.WO/2022/133252MUTATIONS IN FELINE ANTIBODY CONSTANT REGIONS
WO 23.06.2022
Int.Class C07K 16/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
Appl.No PCT/US2021/064097 Applicant ZOETIS SERVICES LLC Inventor CAMPOS, Henry, Luis
The invention relates generally to feline antibody variants and uses thereof. Specifically, the invention relates to mutations in the constant region of feline antibody for improving various characteristics.
8.WO/2022/133282METHODS OF CELL THERAPIES
WO 23.06.2022
Int.Class A61K 35/28
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
28Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
Appl.No PCT/US2021/064152 Applicant OSSIUM HEALTH, INC. Inventor WOODS, Erik, J.
Described herein are methods of cell therapies. Also described herein are methods of generating donor derived T cells in an organ transplant recipient, by administering bone marrow stem cells to the organ transplant recipient about 1 to about 30 days after the organ transplant recipient receives one or more organ transplants.
9.WO/2022/133492COMPOSITIONS AND METHODS FOR GENERATING ANTI-TUMOR IMMUNE RESPONSE
WO 23.06.2022
Int.Class A61K 31/496
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
Appl.No PCT/US2021/073007 Applicant BEYONDSPRING PHARMACEUTICALS, INC. Inventor HUANG, Lan
Disclosed herein are compositions comprising dehydrophenylahistin analogs such as plinabulin and an anti-CD47 agent for treating cancer. Also disclosed here are methods of treating cancer by co-administering the dehydrophenylahistin analog and one or more anti-CD47 agent to a subject in need thereof. Some embodiments, the one or more anti-CD47 agent is an anti-CD47 antibody molecule capable of binding CD47, as well as fragments of these monospecific antibodies that are immunologically active and still bind to CD47.
10.WO/2022/127401CHIMERIC ANTIGEN RECEPTOR TARGETING CD123 AND USE THEREOF
WO 23.06.2022
Int.Class C07K 16/28
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
16Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18against material from animals or humans
28against receptors, cell surface antigens or cell surface determinants
Appl.No PCT/CN2021/127505 Applicant BEIJING IMMUNOCHINA PHARMACEUTICALS CO., LTD. Inventor HE, Ting
Provided in the present invention is a single-chain antibody scFv that specifically binds to CD123, including an amino acid sequence selected from SEQ ID NOs: 56, 57, 58, 59, 60 and 61. Also provided is a chimeric antigen receptor targeting CD123, including an amino acid sequence selected from SEQ ID NOs: 65, 66, 67, 68, 69 and 70. Further provided are a nucleic acid molecule encoding the scFv or chimeric antigen receptor, a vector and cell containing the nucleic acid molecule, and the use of the antibody, chimeric antigen receptor, nucleic acid molecule, vector or cell in the preparation of a drug for treating tumors expressing CD123.